Comparative Study
English Abstract
Journal Article
Add like
Add dislike
Add to saved papers

[Comparison of immunosuppressive effects between human placental MSCs derived from fetal and maternal origins on the rejection of allogenic skin grafts in mice].

OBJECTIVE: To compare the immunosuppressive effects of maternal and fetal placental mesenchymal stem cells (mPMSCs and fPMSCs, respectively) on the rejection of allogenic skin transplants in mice, and further to investigate the mechanism underlying this suppression.

METHODS: The mPMSCs and fPMSCs were isolated from human term placentas. The expressions of cell surface markers were detected by flow cytometry. Cell proliferation capacity was characterized by MTT colorimetric assay. CD200 protein expressed on fPMSCs was neutralized with streaming monoclonal antibodies, and mPMSCs were infected with adenovirus expression vector carrying CD200 cDNA. For skin transplantation, 60 C57BL/6 mice were randomly divided into 6 groups as skin transplant recipients, and ICR mice served as skin donors. After establishment of the allogenic skin transplants, recipient mice of the 6 groups were intravenous injected respectively with PBS, mPMSCs, fPMSCs, fPMSCs combined with anti-CD200 antibodies, mPMSCs with CD200 expressing vectors, and mPMSCs with empty vectors. The conditions and survival time of the skin grafts were inspected daily, and the expressions of interleukin 17 (IL-17), interferon γ (IFN-γ), tumor necrosis factor α (TNF-α) and interleukin 12 (IL-12) in blood and spleen were measured at the end of the study by ELISA and reverse transcription PCR.

RESULTS: The majority (>70%) of fPMSCs were detected CD200 positive, while only a minor fraction (about 2%) of CD-200 positive cells were seen in mPMSCs. In the allogenic skin graft mice, the graft survival time in both mPMSCs- and fPMSCs-treated groups were significantly longer than that in PBS group [(5.6±1.17) days], while the fPMSCs group [(10.6±1.43) days] was more dominant than mPMSCs group [(7.7±1.42) days]. Neutralizing anti-CD200 antibody reduced the graft survival [(8.2±1.14) days] of the fPMSCs group to the level of that in mPMSCs group, while enforced expression of CD200 increased the graft survival [(10.7±1.34) days] of the mPMSCs group to the level of the fPMSCs group. The empty vector-transfected mPMSCs showed a similar effect on graft survival [(7.8±1.32) days] as that in mPMSCs group, longer than PBS group but shorter than fPMSCs and mPMSCs combined with CD200 groups. Comparing with PBS group, the expressions of IL-17, IFN-γ and TNF-α were significantly reduced in mPMSCs and fPMSCs groups. The reduction of these cytokine expressions in the fPMSCs group was neutralized when anti-CD200 antibody was applied, while this reduction in the mPMSCs-treated mice was further enhanced when the mPMSCs were enforced to express CD200.

CONCLUSION: The immunosuppressive effect of fPMSCs on the rejection of allogenic skin transplantation was higher than that of mPMSCs, and this difference was partially contributed by CD200 signaling pathway. The mechanism of this suppression may mediate the inhibition of IL-17, IFN-γ, TNF-α and IL-12 expressions. The fPMSCs may be a suitable choice for immunosuppression on skin transplantation.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app